Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Celecoxib in R0 Resection Pancreatic Cancer
NCT03498326Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2018
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of celecoxib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Apr 2018; status: recruiting.
02
Drugs
celecoxib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03498326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498326.